8-K: Myriad Genetics Announces Leadership Transition, Appoints Sam Raha as CEO

Myriad Genetics announced the appointment of Samraat S. Raha as CEO, succeeding Paul J. Diaz, and Mark S. Verratti as COO, effective April 30, 2025, alongside Q4 and full-year 2024 financial results.

Summary

• Myriad Genetics reported its Q4 and full-year 2024 financial results on February 24, 2025.
• Full-year 2024 revenue reached $838 million, an 11% increase year-over-year.
• Q4 2024 revenue was $211 million, a 7% increase year-over-year, driven by Pharmacogenomics (14%) and Prenatal (12%) testing.
• The GAAP gross margin for Q4 2024 was 71.7%, up 300 basis points year-over-year.
• GAAP net loss for Q4 and full-year 2024 was $(43) million and $(127) million, respectively.
• Adjusted EBITDA for Q4 and full-year 2024 was $11 million and $40 million, respectively.
• As of December 31, 2024, cash plus availability to borrow was approximately $158 million.
• The company reiterated its 2025 financial guidance with a revenue range of $840 $860 million and an adjusted EPS range of $0.07 $0.11.
• Myriad Genetics entered into a strategic collaboration with PATHOMIQ to add AI technology to its Oncology portfolio.
• Samraat S. Raha was appointed as President and CEO, effective April 30, 2025, replacing Paul J. Diaz, who will become a consultant.
• Mark S. Verratti was promoted to COO, effective April 30, 2025.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive revenue growth and strategic initiatives, but also acknowledges challenges like the UNH coverage change and net losses. The leadership transition is framed positively, suggesting confidence in the company's future.

Positives

• Myriad Genetics achieved double-digit revenue growth for the second consecutive year.
• The company's gross margin improved, indicating increased efficiency.
• Strategic collaboration with PATHOMIQ enhances the Oncology portfolio with AI technology.
• The company has a strong cash position and access to additional borrowing capacity.
• The company is launching new products, including Prequel with 8-week Gestational Age, Foresight Universal Plus, and Precise Tumor.
• The company is developing future launches of FirstGene, Precise Liquid, and Precise MRD.

Negatives

• Myriad Genetics reported a GAAP net loss of $(43) million for Q4 2024 and $(127) million for the full year.
• UnitedHealthcare (UNH) will discontinue coverage of multi-gene panel pharmacogenetic testing, including GeneSight, effective in the first half of 2025, impacting approximately $45 million in annual revenue.
• Tumor profiling revenue decreased 4% for the three months ended December 31, 2024.

Risks

• Changes in governmental or private insurers coverage and reimbursement levels for the company's tests could negatively impact revenue.
• Increased competition and the development of new competing tests could erode market share.
• The company may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all.
• The company may not be able to secure additional financing to fund its business, if needed, in a timely manner or on favorable terms.
• The company may be unable to comply with financial or operating covenants under the company's credit or lending agreements.

Future Outlook

Myriad Genetics anticipates continued growth in 2025, with revenue projected to be between $840 and $860 million and adjusted EPS between $0.07 and $0.11. The company plans to launch new products and leverage its multi-year investment program to drive growth and profitability.

Management Comments

• 'There is a lot for Myriad Genetics to be proud of in 2024. We generated 11% revenue growth over 2023, making this our second consecutive year of double-digit growth, and $40 million in adjusted EBITDA,' said Paul J. Diaz, President and CEO, of Myriad Genetics.
• 'We believe 2025 will be another year of opportunity for our stakeholders as Myriad Genetics continues to grow and has the financial flexibility to continue to invest in research and development and technology innovations to achieve our Mission and Vision to advance health and well-being for all by helping people take control of their health,' said Paul J. Diaz, President and CEO, of Myriad Genetics.
• 'I am honored to take on the leadership of Myriad at this pivotal point in the Company's evolution and I am grateful for Paul's leadership in both transforming the Company and delivering a foundation of profitable growth,' said Mr. Raha.
• 'I am now looking forward to leading the team and accelerating our strategy to drive continued growth and profitability through our comprehensive portfolio and future innovation, while continuing to leverage the Company's multi-year investment program and focusing on the needs of patients and the healthcare providers who serve them,' said Mr. Raha.

Industry Context

The collaboration with PATHOMIQ reflects a broader trend in the diagnostics industry towards incorporating AI to enhance precision and efficiency. The updated NCCN guidelines highlight the increasing importance of comprehensive genetic and tumor genomic insights in cancer care, aligning with Myriad's product offerings.

Comparison to Industry Standards

• Myriad Genetics' revenue growth of 11% in 2024 is comparable to other companies in the molecular diagnostics space, such as Exact Sciences, which has also experienced significant growth in recent years.
• The company's focus on expanding its oncology portfolio with AI-driven solutions mirrors the strategies of companies like Roche and Illumina, which are investing heavily in personalized medicine and data analytics.
• The collaboration with MD Anderson Cancer Center is similar to partnerships between other diagnostic companies and leading cancer centers, such as Foundation Medicine's collaboration with Dana-Farber Cancer Institute, to accelerate the development and validation of new assays.

Management Changes

Stakeholder Impact

• Shareholders can expect continued growth and innovation under new leadership.
• Employees will experience changes in leadership roles and potential restructuring.
• Patients will benefit from new AI-driven diagnostic tools and expanded testing options.
• Healthcare providers will have access to more comprehensive genetic and tumor genomic insights to guide treatment decisions.

Next Steps

• Commercially launch the first AI-driven prostate cancer test later in 2025.
• Continue clinical evaluation and development of Myriad's molecular residual disease (MRD) assay.
• Continue the search for a new Chief Commercial Officer (CCO).

Key Dates